EU EMA Veterinary Medicines: QA Alimentary Tract — SGLT2 Inhibitors for Diabetes and Obesity in Dogs, Cats and Horses

Overview

The ATCvet QA category covers the alimentary tract and metabolism. Within the EMA Union Product Database (medicines-output-medicines-report, generated 20/07/2026), the pet-relevant QA medicines are concentrated in two pharmacological groups: SGLT2 inhibitors for diabetes (QA10) and antiobesity preparations (QA08). All are Veterinary category (Category = "Veterinary") with EMA product numbers prefixed EMEA/V/C/.

SGLT2 Inhibitors: Canine and Feline Diabetes

Bexatil (bexagliflozin) — EMEA/V/C/006300

• INN: Bexagliflozin (INN: bexagliflozin)
• Active substance: bexagliflozin
• Species: Cats
• Status: Opinion
• Pharmacotherapeutic group: Drugs used in diabetes
• Indication: For the treatment of cats newly diagnosed with diabetes mellitus to reduce hyperglycaemia and to improve hyperglycaemia-associated clinical signs
• Marketing authorisation holder: Elanco GmbH

Scovella (velagliflozin) — EMEA/V/C/006610

• INN: Velagliflozin (INN: velagliflozin)
• Active substance: velagliflozin
• Species: Horses
• Status: Opinion
• Pharmacotherapeutic group: Drugs used in diabetes
• Indication: For the treatment of hyperinsulinaemia and associated clinical signs (e.g., laminitis) in insulin-dysregulated horses and ponies
• Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH

Note on ATCvet Code

Both products carry ATCvet code QA10BK90 — the "BK90" suffix indicates "other blood glucose lowering drugs, excl. insulins," a subcategory of QA10 (drugs used in diabetes).

Antiobesity Preparations for Dogs

Slentrol (dirlotapide) — EMEA/V/C/000116

• INN: Dirlotapide (INN: dirlotapide)
• ATCvet code: QA08AB91
• Species: Dogs
• Status: Withdrawn
• Pharmacotherapeutic group: Antiobesity preparations, excl. diet products
• Indication: As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight-management programme including dietary restriction and increased physical activity
• Marketing authorisation holder: Zoetis Belgium SA

Yarvitan (mitratapide) — EMEA/V/C/000113

• INN: Mitratapide (INN: mitratapide)
• ATCvet code: QA08AB90
• Species: Dogs
• Status: Withdrawn
• Pharmacotherapeutic group: Antiobesity preparations, excl. diet products
• Indication: As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight management programme
• Marketing authorisation holder: Janssen Pharmaceutica N.V.

Microvascular/Bone Morphogenetic Protein

TruScient (dibotermin alfa) — EMEA/V/C/002000

• INN: Dibotermin alfa (INN: dibotermin alfa)
• ATCvet code: QM05BC01
• Species: Dogs
• Status: Withdrawn
• Pharmacotherapeutic group: Bone morphogenetic proteins
• Indication: Osteoinductive agent for use in the treatment of long-bone fractures as an adjunct to standard surgical care using open reduction and internal fixation techniques
• Marketing authorisation holder: Zoetis Belgium SA

Note: Although QM05BC01 is musculo-skeletal (QM05), it is listed in the QA alimentary tract data and appears in the QA-related product family.

Summary Table

Source: EMA medicines-output-medicines-report_en.xlsx, dataset generated 20/07/2026 - 18:00, accessed via https://www.ema.europa.eu/en/medicines/download-medicine-data.